...
首页> 外文期刊>Journal for ImmunoTherapy of Cancer >P01.17?Tim-3/Galectin-9 pathway controls the ability of malignant cells to escape host immune surveillance. Regulatory mechanisms and therapeutic targets
【24h】

P01.17?Tim-3/Galectin-9 pathway controls the ability of malignant cells to escape host immune surveillance. Regulatory mechanisms and therapeutic targets

机译:P01.17?Tim-3 / Galectin-9途径控制恶性细胞逃避宿主免疫监测的能力。监管机制和治疗目标

获取原文
           

摘要

Background Human cancer cells implement a variety of biochemical mechanisms which allow them to escape host immune surveillance resulting in disease progression. We have reported that the immune receptor Tim-3 and its natural ligand and possible trafficker galectin-9 determine the capability of human acute myeloid leukemia (AML) cells to evade cytotoxic immune attack. 1 Our further studies demonstrated that breast, colorectal and other human solid malignant tumour cells display high activity of this pathway 2 which can also be used for immune evasion. It is, however, important to understand the mechanisms which regulate the biochemical activity of Tim-3/galectin-9 pathway and expression of its components as well as the molecular basis of its capability to impair anti-cancer activity of cytotoxic lymphoid cells. Materials and Methods In this study we used human cancer and non-malignant cell lines as well as primary human malignant tumour samples. We also used primary human T cells and natural killer (NK) cells. Western blot analysis, ELISA, quantitative real-time PCR, on-cell Western, immunohistochemistry, flow cytometry and biochemical assays were used as key instrumentals to conduct measurements. Results We found that galectin-9 is used by human cancer cells to escape host immune surveillance. Cancer cells use various biochemical pathways to overexpress galectin-9. Regardless the biochemical background, transforming growth factor-beta (TGF-β) and transcription factor Smad-3 play crucial role in galectin-9 expression in human cancer cells. We identified the key receptors through which galectin-9 can then trigger killing of cytotoxic T lymphocytes and impairing of anti-cancer activity of natural killer cells. Conclusions In this work, we report the biochemical mechanisms underlying overexpression of galectin-9 in human malignant tumour cells and its differential effects on human cytotoxic lymphoid cells.
机译:背景技术人癌细胞实施各种生化机制,使它们允许它们逃避导致疾病进展的宿主免疫监测。我们据报道,免疫受体TIM-3及其天然配体和可能的贩运者Galectin-9确定人急性髓性白血病(AML)细胞逃避细胞毒性免疫发作的能力。 1我们的进一步研究表明,乳腺,结直肠和其他人类固体恶性肿瘤细胞显示出该途径2的高活性,其也可用于免疫逃避。然而,了解调节Tim-3 / Galectin-9途径的生物化学活性的机制和其组分的表达以及其损害细胞毒性淋巴细胞抗癌活性的分子基础的机制是重要的。本研究中的材料和方法我们使用人癌和非恶性细胞系以及原发性人体恶性肿瘤样品。我们还使用初级人T细胞和天然杀伤(NK)细胞。 Western印迹分析,ELISA,定量实时PCR,细胞内,免疫组化,流式细胞术和生物化学测定用作进行测量的关键乐器。结果我们发现人癌细胞使用Galectin-9来逃避宿主免疫监测。癌细胞使用各种生物化学途径来过表达Galectin-9。无论生化背景,转化生长因子-β(TGF-β)和转录因子Smad-3在人癌细胞中的Galectin-9表达中发挥至关重要的作用。我们鉴定了Galectin-9的关键受体,然后可以引发杀死细胞毒性T淋巴细胞和天然杀伤细胞抗癌活性的损害。结论在这项工作中,我们在人体恶性肿瘤细胞中报告了过表达过表达的生化机制及其对人细胞毒性淋巴细胞的差异影响。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号